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introduction: Recombinant human soluble thrombomodulin (rTM) is reportedly excreted 
by the kidneys; therefore, the recommended dose for patients with renal impairment 
is one-third of the standard dose. The aim of this study was to evaluate whether this 
reduced dose of rTM achieves effective drug concentrations that are comparable to 
those of the standard dose in treating sepsis-induced disseminated intravascular coag-
ulation (DIC) during continuous hemodiafiltration (CHDF).
Methods: Eight patients in an intensive care unit were randomized to receive either 
reduced-dose (0.02  mg/kg, n =  4) or standard-dose (0.06  mg/kg, n =  4) rTM. We 
evaluated the effect of standard dose in comparison to that of reduced dose on the 
pharmacokinetics (PKs) of rTM for the sepsis-induced DIC patients receiving CHDF. 
Patients received rTM during a 30-min infusion for six consecutive days. PK parameters 
of rTM were analyzed using the one-compartment model.
results: The elimination half-life, clearance (T1/2), and distribution volume of sTM 
were similar between the reduced and standard doses. The maximum concentration 
(Cmax) and area under the concentration–time curve (AUC) of sTM were approximately 
2.5 times higher with standard-dose daily infusions than that with reduced-dose drip 
infusions (p = 0.041 and 0.062, respectively). The time when the blood concentration of 
sTM was >500 ng/mL, i.e., the holding time, was significantly longer with standard-dose 
infusions than those with reduced dose (p = 0.039).
conclusion: rTM displayed dose-dependent PK behavior at clinically relevant doses. 
During CHDF, effective blood concentration of rTM was not achieved with the reduced 
dose, and rTM was found to not bioaccumulate. Therefore, this pilot study suggests that 
reducing the rTM dose is unnecessary, even in sepsis-induced DIC patients who require 
CHDF. However, we need to perform a definitive study to determine the dosage of rTM 
for the case.
Keywords: coagulopathy, acute kidney injury, renal dysfunction, renal replacement therapy, sepsis
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inTrODUcTiOn
Severe sepsis continues to be life threatening and the most com-
mon cause of death in intensive care units (ICUs) (1). Mortality 
from sepsis remains high; therefore, new therapies are urgently 
needed. In the pathophysiology of severe sepsis, disseminated 
intravascular coagulation (DIC) has been recently recognized 
to play a key role and to be a therapeutic target. However, 
antithrombin-III (ATIII) and tissue factor pathway inhibitor 
had no effect on mortality in clinical trials (2, 3). Moreover, one 
of the anticoagulation factors, activated protein C (APC), was 
promoted as an antiseptic agent (i.e., Xigris™) but was later with-
drawn owing to the negative results in the PROWESS SHOCK 
trial (4). Currently, there is no natural anticoagulant for the 
treatment of sepsis-induced DIC. However, recombinant human 
soluble thrombomodulin (rTM, or ART-123) was reported to be 
a promising “sepsis drug” and was found to regulate inflamma-
tion and coagulopathy (5). rTM promotes protein C activation 
by thrombin, resulting in the formation of APC. Thereafter, APC 
inhibits thrombin generation by inactivating coagulation factors 
Va and VIIIa to interrupt activation of blood coagulation (6). 
APC also has anti-inflammatory properties, interfering especially 
with the activation of complement and the inactivation of high 
mobility group box 1 (HMGB1), a late phase death mediator in 
severe sepsis (7).
Recombinant human sTM has been marketed as a novel 
anticoagulant for DIC in Japan since 2008. Continuous hemo-
diafiltration (CHDF) is widely accepted as an effective modal-
ity for patients with severe sepsis as a countermeasure against 
hypercytokinemia and renal dysfunction (8, 9). Indeed, in a study 
of 29,269 critically ill patients, 47.5% of patients with acute renal 
failure had simultaneous septic shock (10). Despite widespread 
use of rTM for management of coagulopathy in patients with 
severe sepsis in Japan, little is known about its pharmacokinetic 
(PK) properties and dosing in the subset of critically ill patients 
experiencing coagulopathy during CHDF.
Nakashima et al. reported that mean urinary recovery of rTM 
within the first 48 h was between 54.3 and 59.8% of dose, which 
means rTM is excreted by the kidneys (11). Therefore, the recom-
mended dose for patients with renal impairment is one-third the 
standard dose. A number of reports suggest that the reduced dose 
for patients with renal impairment is too conservative, resulting 
in underdosing. As underdosing is a serious problem, we investi-
gated the PKs of standard- and reduced rTM with sepsis during 
continuous hemofiltration.
PaTienTs anD MeThODs
Patients
After approved by the institutional ethics committee, written 
informed consent was obtained from patients or their next of 
kin. Between September 2010 and August 2012, patients who 
were admitted to the mixed medical-surgical ICU of the Chiba 
University Hospital, Japan, were eligible for enrollment into the 
study, if they met the following criteria: (1) diagnosed with severe 
sepsis that would require CHDF as continuous renal replacement 
therapy and/or as a countermeasure against hypercytokinemia (8) 
for more than 24 h; (2) Japanese Association of Acute Medicine 
DIC criteria score of ≥4 (12), (3) at least 18 years of age, and (4) 
written informed consent was provided.
Patients were excluded if they had (1) chronic kidney 
diseases; (2) significant intracranial, pulmonary, or digestive 
hemorrhages; (3) hypersensitivity to rTM; or (4) a pregnancy or 
suspected pregnancy.
The diagnosis of severe sepsis was made when a patient 
met the criteria proposed by the American College of Chest 
Physicians/Society of Critical Care Medicine Consensus 
Conference (13).
This trial was registered at the UMIN-Clinical Trials Registry 
(UMIN000004074).
renal replacement Therapy
Vascular access was obtained by insertion of a flexible, double-
lumen catheter. The operation of the CHDF system was moni-
tored with a personal bedside console (JUN-500/505; Junken 
Medical Co., Ltd., Tokyo, Japan). CHDF was performed using 
a polymethylmethacrylate (PMMA) membrane hemofilter with 
a membrane surface area of 1.0 m2 (Hemofeel CH-1.0N; Toray 
Medical Co., Ltd., Tokyo, Japan). Nafamostat mesilate (Futhan; 
Torii Pharmaceutical Co., Ltd., Tokyo, Japan), a synthetic protease 
inhibitor with anticoagulant properties, was used as an anticoagu-
lant, with the dose adjusted to maintain an activated coagulation 
time of 150–170 s. The operating conditions for PMMA-CHDF 
were as follows: blood flow rate (QB), 80–120 mL/min; dialyz-
ate flow rate (QD), 1 L/h with sterile bicarbonate solution and 
500  mL/h; substitution flow rate (QS), usually 500  mL/h with 
sterile bicarbonate Ringer’s solution in the postdilution mode 
but controlled by the attending physician based on total water 
balance and hemodynamic state.
study Design
This study was a single-center, randomized, open, comparative 
design (Figure  1). The sepsis-induced DIC patients received 
rTM either at reduced dose (0.02 mg/kg, n = 4) or standard dose 
(0.06 mg/kg, n = 4) for six consecutive days. PK analyses were 
performed during the time of rTM administration. The sampling 
times were: (1) prior to the start of dosing, PD; (2) 30 min after 
initial administration, day 0; (3) prior to the second administra-
tion, day 1; (4) immediately after the sixth administration, day 5; 
and (5) 24 h after the end of the sixth administration, day 6.
This study protocol was approved by the Institutional Review 
Board of Chiba University Hospital in conformity with the 
Helsinki Protocol.
Drug administration and sampling
All patients received rTM (ART-123, Recomodulin®; Asahi Kasei 
Pharma Corporation Ltd., Tokyo, Japan), which was reconsti-
tuted according to the manufacturer’s instructions. The solutions 
were given via an infusion pump over a 30-min interval. Initial 
sampling was done immediately after dosing completion.
All blood samples were drawn from indwelling arterial 
catheters into vacuum blood collection tubes containing 
sodium citrate. The blood was centrifuged (3,000  rpm for 
10 min), and plasma separated immediately. Similarly, aliquots 
FigUre 1 | Flow chart of patient selection disseminated intravascular coagulation and recombinant human soluble thrombomodulin.
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of dialyzate and filtrate were collected. All samples were kept 
at −80°C until assayed.
analytical Methods
The plasma rTM and soluble TM concentrations were determined 
with enzyme-linked immunosorbent assay (ELISA), using two 
different mouse monoclonal antibodies against thrombomodulin 
(14). The ELISA can measure the active form of TM-α because 
the results of ELISA correlated with those of a functional assay 
(15). Serum levels of interleukin-6 (IL-6) were measured daily 
with chemiluminescence enzyme immunoassay (CLEIA), using 
a rapid measurement system (Human IL-6 CLEIA, Fujirebio, 
Tokyo, Japan) that had been reported previously (16). HMGB1 
was also measured by a commercial ELISA kit, according to 
manufacturer’s instructions (Shino-Test Co., Tokyo, Japan).
PK analysis
Because the PK of rTM can be described by a one-compartment 
model (14), PK parameters were determined by one-compart-
ment analysis, using the Phoenix® WinNonlin® software (ver. 
1.4). During the dosing period, the duration during which sTM 
levels were ≥500 ng/mL was recorded. We adapted 500 ng/mL as 
the effective concentration of sTM for holding time (the duration 
when the blood concentration of sTM was >500 ng/mL) because 
the dosage amount of rTM in clinical practice was determined 
by estimation from a phase 2 clinical study through all admin-
istration periods (14). Clinical test data were collected daily and 
correlated with the clearance of rTM (CL).
statistical analysis
Values are reported as median and interquartile range, or 
mean ±  SD (or SEM), depending on the variables. Statistically 
significant differences in the mean values between two groups 
were evaluated by the Wilcoxon signed-rank test.
Associations between the CL calculated in the present study 
and the clinical parameters were assessed with the Spearman’s 
rank correlation test.
Statistical significance was defined as a p-value of less than 
0.05. All statistical analyses were performed using the GraphPad 
PRISM 5, version 5.04 (GraphPad Software, San Diego, CA, USA) 
for Windows.
resUlTs
Patient Demographics
Eight patients were enrolled in the study and randomly allo-
cated to two groups (reduced-dose and standard-dose admin-
istration, Figure 1). Although the cause of the sepsis-induced 
DIC in each group varied, age, gender, body weight, severity 
scores, and clinical parameters were not markedly different 
(Table 1). Both groups included patients with pneumonia and 
severe acute pancreatitis.
Two of the eight patients (one patient in each group) died 
during the course of their ICU stay. In addition, two of the 
eight (one patient in each group) had bleeding-related adverse 
events during their ICU stay. One of these patients experi-
enced bleeding because of the gastric fiberscope contacting 
the duodenal bulb during enteral tube insertion. Bleeding in 
the other patient was caused by repeated debridement for 
infected gas gangrene. The bleeding complications were not 
life threatening, none of the patients required red blood cell 
transfusions, and both survived (Table S1 in Supplementary 
Material). Therefore, any causal relationship between rTM 
infusion and these bleeding-related events was not defined. 
Although the number of patients included in the present study 
was less, no evaluated outcomes were different between the 
reduced- and standard-dose groups (Table  1).
Table 2 | Plasma sTM concentrations before and after chDF after the 
first rTM infusion on day 1.
Pre-chDF 
hemofilter
Post-chDF 
hemofilter
p-Value
Reduced-dose 
rTM (ng/mL) (n = 4) 
median (range)
247.7 (208.2–282.6) 260.1 (223.8–302.5) 0.250
Standard-dose 
rTM (ng/mL) (n = 4) 
median (range)
637.4 (189.6–793.5) 653.3 (444.5–1101.8) 0.125
CHDF, continuous hemodiafiltration; sTM, soluble thrombomodulin; rTM, recombinant 
human soluble thrombomodulin.
p-values with Wilcoxon signed-rank test.
FigUre 2 | soluble thrombomodulin (sTM) concentration of pre- and 
post- continuous hemodiafiltration hemofilter right after the first infusion 
sTM. The blue lines indicate the sTM concentrations of regular-dose group. The 
gray lines indicate the sTM concentrations of reduced-dose group. An excluded 
case from pharmacokinetic analyses was shown with black color which seems 
to show unusually low concentration of sTM at pre-CHDF hemo filter under 
standard-dose infusion. The two patients complicated with a hemorrhagic 
complication were indicated as red closed circle in each dosage group.
Table 1 | characteristics of the study patients.
reduced-dose rTM (0.02 mg/kg, n = 4) standard-dose rTM (0.06 mg/kg, n = 4)
Age (year) mean ± SD 67.8 ± 18.5 65.3 ± 17.5
Gender (male/female) 3/1 2/2
Weight (kg) median (range) 67.6 (40.5–75.7) 56.4 (49.4–58.6)
APACHE II score median (range) 22.5 (18–32) 28 (14–34)
SOFA score median (range) 13 (11–14) 12 (11–13)
SIRS score median (range) 3 (1–4) 2.5 (0–4)
JAAM DIC score median (range) 6.5 (4–8) 5.5 (5–8)
Cause of sepsis-induced DIC •	 Enterocolitis
•	 Bacteremia
•	 Aspiration pneumonia
•	 Bacterial translocation due to SAP
•	 Gas gangrene
•	 Pneumocystis jiroveci pneumonia
•	 Urinary tract infection
•	 Bacterial translocation due to SAP
sTM on admission (ng/mL) mean ± SD 9.30 ± 2.58 6.16 ± 0.65
Plt on admission (×104/μL) mean ± SD 4.45 ± 0.10 5.05 ± 1.95
Creatinine (mg/dL) on admission mean ± SD 2.99 ± 1.04 1.41 ± 0.76
Cystatin C (mg/L) on admission mean ± SD 2.34 ± 0.55 1.56 ± 0.28
CLcr (mL/min) mean ± SD 22.3 ± 9.83 52.1 ± 37.3
Interleukin-6 (pg/mL) on admission Geometric mean ± SD 2214.5 ± 31.2 692.3 ± 16.3
HMGB1 on admission (ng/mL) mean ± SD 10.51 ± 6.58 10.93 ± 8.21
No. of days in ICU stay median (range) 14.5 (9–33) 20 (15–21)
28-day survival (%) 3 (75%) 3 (75%)
No. of days of CHDF median (range) (days) 7.0 (4–13) 5.5 (3–9)
DIC resolution at day 6 of rTM administration (%) 1 (25%) 2 (50%)
Bleeding-related adverse events (%) 1 (25%) 1 (25%)
Creatinine clearance (CLcr) was calculated with Cockcroft–Gault formula.
SAP, severe acute pancreatitis; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; SIRS, systemic inflammatory response 
syndrome; JAAM, Japanese Association of Acute Medicine; DIC, disseminated intravascular coagulation; HMGB1, high mobility group box 1; sTM, soluble thrombomodulin; rTM, 
recombinant human soluble thrombomodulin; ICU, intensive care unit; CHDF, continuous hemodiafiltration; Plt, platelet count.
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Pre- and Post-chDF sTM concentrations
The sTM shed from the endothelial cell surface before admin-
istration was similar between the reduced- and standard-dose 
groups, and the concentrations were quite low relative to those 
after administration (Table  1). sTM concentrations pre- and 
post- CHDF hemofilter were measured on day 1, and the value in 
each patient was relatively elevated than that before administra-
tion (Figure 2). However, the sTM concentration of pre-CHDF 
plasma was statistically equivalent to that of post-CHDF plasma 
in both the reduced-dose and standard-dose groups (Table 2). 
The sTM concentrations in hemofiltrates of all patients were 
undetectable (i.e., below the limit of detection of 1  ng/mL). 
Therefore, rTM was found to be removed by neither adsorption 
nor filtration during CHDF.
PK Parameters
Table 3 shows PK parameters. The elimination half-life (T1/2), CL, 
and distribution volume (Vd) of rTM were similar between the 
FigUre 3 | Plasma soluble thrombomodulin (sTM) concentration with respect to time in sepsis-induced disseminated intravascular coagulation 
patients treated with continuous hemodiafiltration, simulated using the one-compartment model sTM. The blue line indicates the theoretical simulating 
lines for sTM concentrations of standard-dose group. The gray line similarly indicates the theoretical simulating lines for sTM concentrations of reduced-dose group. 
The blue and gray open circles indicate actual sTM concentrations of all time points for standard- and reduced-group, respectively. An excluded case from 
pharmacokinetic analyses was shown with black color. The two patients complicated with a hemorrhagic complication were indicated as red closed circle in each 
dosage group. Data points represented as mean ± SD.
Table 3 | Pharmacokinetics of rTM.
reduced-dose rTM 
n = 4
standard-dose rTM 
n = 3
p-Value
T1/2 (h) 41.0 ± 7.5 31.0 ± 20.9 0.203
Cmax (ng/mL) 615.6 ± 102.6 1570.9 ± 899.5 0.041
AUC (ng⋅h/mL) 57631.6 ± 9577.0 140233.9 ± 91487.5 0.062
Vd (mL/kg) 91.8 ± 13.5 89.3 ± 24.9 0.434
CL (mL/h/kg) 1.60 ± 0.4 2.60 ± 1.2 0.113
>500 ng/mL sTM 
holding time, h
33.8 ± 28.4 143.3 ± 96.4 0.039
rTM, recombinant human soluble thrombomodulin; T1/2, elimination half-life; Cmax, 
maximum concentration; AUC, area under the concentration–time curve; Vd, 
distribution volume; CL, clearance of rTM; sTM, soluble thrombomodulin.
p-values with unpaired t-test, one-tailed.
Maximum concentration (Cmax) and AUC were estimated assuming that the frequency 
of administration was six in each series. Values are mean ± SD.
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p = 0.062, respectively). The time when the plasma concentration 
of sTM was >500 ng/mL, i.e., the holding time, was significantly 
longer with standard dose than with reduced-dose infusions 
(143.3 ± 96.4 vs 33.8 ± 28.4 h, p = 0.039).
Figure 3 shows the predicted sTM concentration curves based 
on the mean PK parameters over 6 days. The actual concentration 
of sTM in one patient in the standard-dose group significantly 
deviated from the theoretical line (Table S2 and Figures S2A,B 
in Supplementary Material). Therefore, the data of this patient 
were excluded from the PK analyses. The sTM concentrations of 
patients with hemorrhagic complications (red circles in Figure 3) 
were relatively low even in standard-dose group.
correlation between cl and clinical 
Parameters
The correlations between CL and clinical parameters at the time 
of admission to the ICU were evaluated as shown in Figure 4A. 
Among 20 markers evaluated, ATIII activity was the only one that 
significantly correlated with CL (Figure 4B, Spearman r = −0.821, 
p =  0.034, n =  7). All the markers for DIC recovered toward 
normal value during the time course in both the reduced- and 
standard-dose groups (Figure S1A in Supplementary Material). 
Serum IL-6 levels, which are widely recognized as useful biomark-
ers of septic inflammation, markedly decreased during the time 
reduced and standard doses (41.0 ± 7.5 vs 31.0 ± 20.9 h, 1.60 ± 0.40 
vs 2.60 ± 1.20 mL/h/kg, and 91.8 ± 13.5 vs 89.3 ± 24.9 mL/kg, 
respectively, mean ± SD). The maximum concentration (Cmax) 
of rTM and the area under the curve (AUC) of rTM were 
approximately 2.5 times higher with standard dose than that with 
reduced-dose infusions (1570.9 ± 899.5 vs 615.6 ± 102.6 ng/mL, 
p = 0.041 and 140233.9 ± 91487.5 vs 57631.6 ± 9577.0 ng/mL/h, 
FigUre 4 | (a) Correlation between clearance of rTM (CL) and clinical 
parameters. Antithrombin-III (ATIII) activity was the only one marker that had 
significant correlation with CL among 20 markers evaluated (Spearman 
r = −0.821, p = 0.034, n = 7). (b) Correlation plots for ATIII activity relative to 
CL. CL was inversely correlated with ATIII activity (Spearman r = −0.821, 
p = 0.034, n = 7). JAAM, Japanese Association of Acute Medicine; DIC, 
disseminated intravascular coagulation; rTM, recombinant human soluble 
thrombomodulin. *p < 0.05 with Spearman’s rank correlation.
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course. However, there was no significant difference between the 
two treatment groups (Figure S1B in Supplementary Material).
DiscUssiOn
The present study is the first to demonstrate that the rTM hold-
ing time is significantly longer with standard dose than with 
reduced-dose infusions during CHDF. This result suggests that 
the efficacy of reduced-dose rTM was insufficient to regulate the 
coagulation system in this setting. The elevation of baseline sTM 
levels was also assessed after daily administration of rTM. The 
T1/2, CL, and Vd of rTM were similar between the reduced and 
standard doses, although the maximum concentration (Cmax) 
and the AUC of rTM were approximately 2.5 times higher with 
the standard dose. Therefore, rTM was found to not bioaccumu-
late in this setting.
Hayakawa et al. demonstrated that the CL of rTM in patients 
with severe renal impairment was similar to that in those without 
renal impairment (17). However, they analyzed the PK based on 
concentrations of rTM after a single infusion of the drug. We 
evaluated the PK of rTM using multiple sampling times (i.e., 
PD, day 0, 1, 2, 5, and 6) with a daily infusion regimen, which 
is generally recommended in the clinical setting. In contrast, 
Mouksassi et al. reported that a 0.06 mg/kg dose of rTM should 
result in drug exposure within the therapeutic range, with mini-
mal risks of bleeding in patients with normal and impaired renal 
functions (18). However, the PK during CHDF was unclear prior 
to the present study.
Tsuruta et  al. reported a formula for CL of rTM as follows: 
0.00162 × WT × CLcr0.175 × (−0.0117 × Hct + 1) × (−0.00374 
×  Age  +  1) (14). We compared the predicted CL using that 
formula with the actual CL in our patients. There was an appar-
ent discrepancy between the actual and predicted CLs of rTM 
(data not shown). Creatinine clearance (CLcr) was regarded as a 
significant covariate for CL, which is supported by the fact that 
this drug is predominantly excreted by the kidney. However, CLcr 
did not significantly correlate with CL in our data (Figure 4A), 
and the CL of rTM was not affected by CHDF in the results of the 
present study.
In order to elucidate the mechanism of CL in renal impair-
ment, we compared CL with the other clinical parameters by 
means of Spearman’s rank correlation. As shown in Figure 4A, 
ATIII activity most significantly correlated with CL among the 
20 cofactors evaluated. Both CL and ATIII activities could be 
associated with the hyperpermeability of patients with severe 
inflammation because of the similarity in their molecular weights 
(i.e., 62 and 63 kDa, respectively). Leakage of both molecules to 
the extravascular space could cause unexplainable CL of rTM in 
sepsis-induced DIC patients with kidney injury. In this regard, 
it was reported that APC could preserve the expression of junc-
tion proteins, such as VE-cadherin for adherens junctions and 
occludin for tight junctions. rTM is known to promote protein C 
activation by thrombin, resulting in the formation of APC (19). 
Therefore, sufficient dosing of rTM may regulate the hyperper-
meability caused by severe sepsis.
A large phase 3 study in subjects with severe sepsis and coagu-
lopathy is currently in progress to evaluate survival benefits of 
rTM (http://ClinicalTrials.gov ID: NCT01598831, accessed 11 
November 2016) (20). The present study should provide great 
impact on the future regimen of rTM. Results from a recent 
report suggest that dose adjustments, which are widely accepted 
clinically, are not necessary in patients with sepsis and DIC, 
regardless of renal impairment (18, 21). The present study pro-
vides novel information that dose adjustment in patients with 
sepsis-induced DIC during CHDF is unnecessary, despite CHDF 
not being able to clear rTM.
The present study has some limitations. First, the patient 
numbers included in this study were smaller than initially 
planned. After starting the present study, we decided to par-
ticipate in another large-scale study, where similar patients with 
DIC were to be included (https://clinicaltrials.gov/ct2/show/
NCT01704001?term=ART-123&rank=1; accessed on January 
14, 2017). In addition, we found that the rTM holding time was 
significantly shorter in the reduced-dose group in preliminary 
analyses. Therefore, we decided to discontinue reduced-dose 
treatments in consideration of patient benefits and improved 
rTM dosage for future studies. While the number of patients 
included in the present study is small, these PK data are valuable 
because they were collected on multiple days (i.e., PD, day 0, 1, 
7Watanabe et al. Pharmacokinetics of rTM during CHDF
Frontiers in Medicine | www.frontiersin.org February 2017 | Volume 4 | Article 15
5, and 6) from patients under such life-threatening conditions. 
Forty-eight sTM concentrations were included for evaluation. 
Furthermore, Cmax and holding time were found to be signifi-
cantly different between the reduced-dose and standard-dose 
groups, even with the small number of patients. Second, neither 
clinical outcome nor complications were evaluated because of 
the heterogeneous patient characteristics, which are typical in 
ICU patient cohorts. Again, our focus was simply to study the 
PK of rTM during CHDF for sepsis-induced DIC. Third, the 
only hemofilter that we used in this study was composed of 
PMMA. In general, PMMA membranes have stronger adsorb-
ing properties than other types of membrane (8). Intriguingly, 
despite these strong adsorbing properties of PMMA, the 
concentration of rTM was higher in the hemofilter outlet than 
in the inlet because adsorption was minimal (Table  2). This 
means that the hemofilter could not remove rTM during CHDF 
through adsorption.
Currently, anticoagulation therapy for sepsis-induced coagu-
lopathy is recognized as a useful therapeutic strategy that is highly 
relevant in a small percentage of septic patients (22), although 
this is not discussed by the Surviving Sepsis Campaign (23). As 
a practical matter, the proper use of rTM, including target illness 
severity and dosage, as evaluated in the present study for sepsis-
induced DIC patients during CHDF, is still obscure. This is true 
even in Japan, where rTM has already gained greater acceptance 
in the marketplace. Due to the anticoagulant properties of rTM, 
the most important concern in treating DIC patients, who are 
susceptible to bleeding, is a serious hemorrhage due to abrupt 
increases in plasma concentration of this drug. Exacerbating this 
concern, it is usually necessary for patients who receive CHDF to 
be infused with additional anticoagulant (e.g., nafamostat mesi-
late). The highest concentration of rTM with no bleeding event 
in the non-clinical toxicology studies was 5400  ng/mL, which 
was originally carried out in monkeys (18). Also, Shirae et  al. 
recently reported that the highest individual simulated Cmax of 
the patients who received regular dose of rTM was 4730 ng/mL 
even though they included patients with severe renal impairment 
on hemodialysis in their study population (21). As for the thera-
peutic range, it is regarded the trough level of rTM as of >500 ng/
mL on the strength of the result of phase 2 study, although there is 
no published report evaluating the dose effectiveness in a clinical 
study (14). Therefore, the baseline level of rTM is regarded as 
>500  ng/mL in clinical settings, although there is no report 
evaluating the dose effectiveness in a clinical study. Therefore, 
a larger cohort study that includes sepsis-induced DIC patients 
of varying severity is warranted to validate the necessity of dose 
titration (18).
cOnclUsiOn
Recombinant human soluble thrombomodulin displayed dose-
dependent PK behavior with the range of doses used in clinical 
settings. Effective blood concentration of rTM was not achieved 
with reduced-dose administration during CHDF; rTM was found 
to not bioaccumulate in this setting. Therefore, it might not be 
necessary to reduce the dose of rTM, even if sepsis-induced DIC 
patients are on CHDF. A prospective comparison of the clinical 
efficacy of the two-dose regimens using a larger patient cohort is 
warranted.
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